Physician profile
David E Phillips
NPI 1962487991
$2,686.33
in general payments reported to CMS, 2019-2025
27 companies · $364 in 2025
The $364 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $92.65 · 2021: $471 · 2022: $483 · 2023: $580 · 2024: $269 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,212.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $514.40 | 2019-2024 | Ofev |
| Astrazeneca Pharmaceuticals LP | $508.25 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $403.68 | 2019-2025 | Trelegy Ellipta |
| Genzyme Corporation | $296.07 | 2022-2025 | |
| Mylan Specialty L.P. | $134.82 | 2022-2024 | Yupelri |
| Amgen INC. | $123.24 | 2022-2023 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $110.97 | 2022-2025 | Dupixent |
| Philips North America LLC | $96.79 | 2019-2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Genentech USA, INC. | $79.60 | 2019-2022 | |
| Insmed, INC. | $60.91 | 2019-2025 | Arikayce |
| Ethicon INC. | $41.86 | 2025 | Monarch Platform |
| Actelion Pharmaceuticals US, INC. | $34.09 | 2019 | |
| Jazz Pharmaceuticals INC. | $27.77 | 2021 | |
| Inogen, INC. | $25.56 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Dexcom, INC. | $23.30 | 2024 | Dexcom G6 Transmitter |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $22.57 | 2025 | Inspire |
| Tactile Systems Technology INC | $22.04 | 2023 | Entre Plus, Flexitouch Plus |
| Viatris Specialty LLC | $21.24 | 2025 | Yupelri |
| Novo Nordisk INC | $20.53 | 2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $19.49 | 2020 | |
| United Therapeutics Corporation | $18.82 | 2023 | Tyvaso |
| Gilead Sciences, INC. | $18.62 | 2022 | |
| Lilly USA, LLC | $18.14 | 2025 | Zepbound |
| Verona Pharma, INC. | $16.03 | 2025 | Ohtuvayre |
| Fisher & Paykel Healthcare INC | $15.77 | 2020 | |
| Sunovion Pharmaceuticals INC. | $11.77 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.